PREDICTION OF ANTI-ALZHEIMER’S ACTIVITY OF FLAVONOIDS TARGETING CD33 THROUGH IN-SILICO APPROACH
Keywords:Alzheimers disease, CD33, Flavonoids, Molecular docking
Objective: Alzheimer's disease (AD) is a progressive, fatal brain disorder that would be putting a growing strain on health and social care systems. Present anti-AD agents are limited in their application due to their adverse effects, toxicity, and limited targets in AD pathology. As a result, it is important to develop an AD-fighting compound. Some flavonoids (such as kaempferol, myricetin, quercetin, and syringetin) have been shown to be effective in the treatment of Alzheimer's disease.
Methods: We chose 284 flavonoids from the NPACT database for molecular docking studies in order to examine their binding interactions with the Alzheimer target protein CD33.
Results: These compounds exhibited significant docking interactions with a variety of targets implicated in the pathogenesis of AD. We chose the top three compounds (Rutin, Morin, and,4,4'-Trihydroxydihydrochalcone) based on the scoring parameter.
Conclusion: These compounds exhibited favorable pharmacokinetic properties, indicating that they could be attractive drug candidates for the treatment of Alzheimer's disease.
2. Khunnawutmanotham N, Chimnoi N, Saparpakorn P, Techasakul S. Synthesis and anti-acetylcholinesterase activity of scopoletin derivatives. Bioorg Chem 2016;65:137-45.
3. Hardy J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
4. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS-amyloid in alzheimer's disease. Science 2010;330:1774-4.
5. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008;83:623–32.
6. Chung SJ, Lee J, Kim SY, You S, Kim MJ, Lee J, et al. Association of GWAS top hits with late-onset al. zheimer disease in Korean population. Alzheimer Dis Assoc Disord 2013;27:250-7.
7. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7:255-66.
8. Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PLoS One 2012;7:e50976.
9. Griciuc A, Serrano Pozo A, Parrado A, Lesinski A, Asselin C, Mullin K, et al. Alzheimer’s disease risk gene CD33 inhibits Microglial uptake of amyloid-beta. Neuron 2013;78:631-43.
10. Airoldi C, La Ferla B, D`Orazio G, Ciaramelli C, Palmioli A. Flavonoids in the treatment of alzheimer’s and other neurodegenerative diseases. Curr Med Chem 2018;25:3228-46.
11. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–61.
12. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91.